<DOC>
	<DOCNO>NCT00136409</DOCNO>
	<brief_summary>The purpose study determine effect ( good bad ) Gleevec patient BCR-negative myeloproliferative disorder include myelofibrosis myeloid metaplasia chronic myelomonocytic leukemia .</brief_summary>
	<brief_title>A Study Gleevec Patients With Idiopathic Myelofibrosis Chronic Myelomonocytic Leukemia ( CMML )</brief_title>
	<detailed_description>Gleevec administer dose 400 mg orally daily . Patients continue receive drug either drug progression development intolerable side effect . Patients assess complete blood count weekly first 8 week monthly physical examination bone marrow examination every 3 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients must clinical diagnosis myelofibrosis myeloid metaplasia chronic myelomonocytic leukemia ( CMML ) . Patients may enter base prior cytogenetic karyotype show absence Philadelphia chromosome . Patients may enter prior completion reverse transcriptionpolymerase chain reaction ( RTPCR ) fluorescent situ hybridization ( FISH ) study , patient subsequently find BCRABL FISH positive remove protocol treatment . FISH perform patient normal karyotype . A PCR sample send patient . The patient myelodysplasia must FrenchAmericanBritish ( FAB ) subtype chronic myelomonocytic leukemia ( CMML ) define peripheral blood monocytosis , less 30 percent blast peripheral blood bone marrow . The patient myelofibrosis myeloid metaplasia one following : agnogenic myeloid metaplasia ( idiopathic myelofibrosis ) , postpolycythemic myeloid metaplasia ( postpolycythemic myelofibrosis ) , postthrombocythemic myeloid metaplasia . Estimated life expectancy 6 month great . Serum bilirubin equal less twice upper limit normal . Serum SGOT SGPT equal le twice upper limit normal . Serum creatinine equal less twice upper limit normal . Age least 18 year . Greater 4 week chemotherapy ( except hydroxyurea ) , radiotherapy , immunotherapy , systemic glucocorticoid therapy ( nonglucocorticoid hormonal therapy allow ) . Systemic glucocorticoid therapy nonmalignant disease allow . The last dose hydroxyurea must 24 hour prior initiation Gleevec . Greater 2 month follow bone marrow peripheral blood stem cell transplantation treatment donor lymphocyte infusion ( DLI ) . Uncontrolled active infection . Pregnancy nurse mother . Patients myelofibrosis myeloid metaplasia chronic myelomonocytic leukemia transform acute myelogenous leukemia . Prior treatment diagnosis acute myelogenous leukemia . Patients Philadelphia positive cytogenetics either peripheral blood bone marrow sample . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 3 . Prior exposure Gleevec . Active central nervous system ( CNS ) disease . Evidence infection human immunodeficiency virus . Active psychiatric mental illness making informed consent careful clinical followup unlikely .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>myelofibrosis</keyword>
	<keyword>agnogenic myeloid metaplasia myelofibrosis</keyword>
	<keyword>CMML</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>imatinib mesylate</keyword>
	<keyword>Gleevec</keyword>
</DOC>